Another breakthrough in overseas expansion! Henlius receives FDA approval for two osteoporosis treatment drugs
September 2, 2025
Source: drugdu
95
On September 1, Henlius Biopharmaceuticals (02696) announced that it had recently received approval from the U.S. Food and Drug Administration (FDA) for the development of two HLX14 (denosumab)-related products, BILDYOS® and BILPREVDA®.The license application was approved.
These two products are used to treat osteoporosis and prevent bone-related events in specific populations, respectively. Specific indications include the treatment of osteoporosis in postmenopausal women and men, glucocorticoid-induced osteoporosis, and bone metastases in patients with multiple myeloma.
https://finance.eastmoney.com/a/202509023502086989.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Breaking the Mold and Forging a New Path! From Insulin Technology Pioneer to Global Innovation Competitor December 4, 2025
- A subsidiary of Kingfriend Pharmaceutical Co., Ltd. has received FDA approval for its self-developed injectable dapavancin December 4, 2025
- Major ophthalmic new drug successfully completed Phase III trials December 4, 2025
- Simcere Pharmaceutical and Wangshan Wangshui have reached an exclusive licensing agreement for deuterium remidevir hydrobromide for new indications such as RSV infection December 4, 2025
- SAL0140 tablets approved for clinical trials for the treatment of chronic kidney disease December 4, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
